<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625441</url>
  </required_header>
  <id_info>
    <org_study_id>FBCG-01-2015</org_study_id>
    <secondary_id>2015-002323-25</secondary_id>
    <nct_id>NCT02625441</nct_id>
  </id_info>
  <brief_title>Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer</brief_title>
  <acronym>BOLD-1</acronym>
  <official_title>A Randomized Phase III Study Comparing Trastuzumab, Pertuzumab Plus Docetaxel (TPD) Followed by 3 Cycles of Chemotherapy to the Current Standard Regimen as the Treatments of Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial compares two systemic treatments for HER2-positive breast
      cancer. The treatments are given either prior to breast surgery (as neoadjuvant treatment) or
      after breast surgery (as adjuvant treatment). In the investigational group (Group A) the
      study participants will receive a combination of two drugs directed at HER2 (two anti-HER2
      antibodies) plus a chemotherapy agent (docetaxel) for a brief duration, and the patients
      allocated to the comparator group (Group B) will be treated with chemotherapy plus one
      anti-HER2 treatment (trastuzumab) for one year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients who have been diagnosed with HER2-positive early breast cancer will
      be randomly allocated in a 1:1 ratio to receive either three 3-weekly cycles of trastuzumab,
      pertuzumab and docetaxel (TPD) for a total duration of 9 weeks, followed by three further
      cycles of chemotherapy (Group A) or three 3-weekly cycles of trastuzumab and docetaxel (TD)
      followed by three further cycles of chemotherapy and single-agent anti-HER2 antibody
      treatment to complete one year of anti-HER2 treatment (Group B). These systemic treatments
      may be administered either prior to breast surgery (as neoadjuvant treatment) or after breast
      surgery (as adjuvant treatment). The study participants are required to have histologically
      verified breast cancer with a moderate to high risk for breast cancer recurrence despite
      macroscopically complete surgery for the breast tumor. The moderate/high risk of breast
      cancer recurrence is defined by presence of cancer in the axillary lymph nodes, or if the
      axillary lymph nodes do not contain cancer, by presence of a tumor larger than one centimeter
      in the breast. The study patients are followed up during the study treatments and after their
      completion with physical examination, blood tests, cardiac tests and, whenever indicated,
      with imaging. Approximately 700 patients will be randomly allocated to each of the two
      groups. The study hypothesis is that the regimen containing TPD may be more effective than
      the Group B treatment despite its brief duration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive disease-free survival</measure>
    <time_frame>7 years</time_frame>
    <description>Time from the date of randomization to cancer recurrence or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>7 years</time_frame>
    <description>Time from the date of randomization to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant disease-free survival</measure>
    <time_frame>7 years</time_frame>
    <description>Time from the date of randomization to distant recurrence of cancer or to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle ejection fractions</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac ejection fraction measured with echocardiography or isotope cardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of the treatments</measure>
    <time_frame>7 years</time_frame>
    <description>Adverse events considered to be related to the treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of life measured with the EuroQol EQ-5D instrument.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1366</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Short anti-HER2 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pertuzumab 840 mg, i.v., then 420 mg i.v., 3-weekly for 3 cycles; Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard anti-HER2 treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles; Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Pertuzumab 420 mg i.v. 3-weekly for 3 cycles</description>
    <arm_group_label>Short anti-HER2 treatment</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year</description>
    <arm_group_label>Standard anti-HER2 treatment</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has provided a written informed consent prior to study-specific screening
             procedures, with the understanding that she has the right to withdraw from the study
             at any time, without prejudice.

          -  Woman &gt; 18 years of age.

          -  Histologically confirmed invasive breast cancer.

          -  HER2-positive breast cancer (preferably assessed with in situ hybridization; CISH,
             FISH or SISH; if not available with immunohistochemistry 3+)

          -  A high risk of breast cancer recurrence with one of the following: i) Pathological N0
             with the longest invasive tumor diameter &gt;10 mm; ii) Histologically confirmed regional
             node positive disease

        Exclusion Criteria:

          -  Presence of distant metastases.

          -  Inflammatory breast cancer.

          -  Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure,
             symptomatic coronary artery disease and cardiac arrhythmia not well controlled with
             medication) or myocardial infarction within the last 12 months.

          -  Left ventricular ejection fraction less than 50% (or under the institutional normal
             reference range) assessed by echocardiography or isotope cardiography.

          -  ER and HER-2 status (via in situ hybridization or immunohistochemistry) not
             determined.

          -  The WHO performance status &gt; 1.

          -  Pregnant or lactating women.

          -  Women of childbearing potential unless using a reliable and appropriate contraceptive
             method. Women must have been amenorrheic for at least 12 months prior to study entry
             to be considered postmenopausal and to have no childbearing potential. Women of
             childbearing potential (menstruating within 12 months of study entry), or with no
             hysterectomy and age &lt; 55, must have a negative pregnancy test at baseline.

          -  Randomization more than 12 weeks after the date of breast surgery.

          -  Organ allografts with immunosuppressive therapy required.

          -  Major surgery (except breast surgery) within 4 weeks prior to study treatment start,
             or lack of complete recovery from the effects of major surgery.

          -  Participation in any investigational drug study within 4 weeks preceding treatment
             start.

          -  Patients with a history of uncontrolled seizures, central nervous system disorders or
             psychiatric disability judged by the investigator to be clinically significant
             precluding study participation.

          -  Multifocal breast cancer when the largest cancer focus is not HER2-positive.

          -  History of another malignancy or contralateral invasive breast cancer within the last
             five years except cured basal cell carcinoma of skin or carcinoma in situ of the
             uterine cervix (exception: patients with bilateral HER2-positive breast cancer are
             eligible).

          -  One or more of the following: Blood hemoglobin &lt; 10.0 g/dL, neutrophils &lt; 1.5 x 109/L;
             platelet count &lt; 120 x 109/L; Serum/plasma creatinine &gt; 1.5 x Upper Limit of Normal
             (ULN); Serum/plasma bilirubin &gt; ULN; Serum/plasma ALT and/or AST &gt; 1.5 x ULN;
             Serum/plasma alkaline phosphatase &gt; 2.5 x ULN

          -  Serious uncontrolled infection or other serious uncontrolled concomitant disease.

          -  Unwilling or unable to comply with the protocol for the duration of the study.

          -  History of hypersensitivity to the investigational products or to drugs with similar
             chemical structures.

          -  Pre-existing motor or sensory neurotoxicity of a severity â‰¥ grade 2 by CTCAE version
             4, unless related to mechanical etiology.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heikki Joensuu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heikki Joensuu, M.D.</last_name>
    <phone>094711</phone>
    <phone_ext>+358</phone_ext>
    <email>heikki.joensuu@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heikki Joensuu, MD</last_name>
      <phone>47173200</phone>
      <phone_ext>09</phone_ext>
      <email>heikki.joensuu@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Raija 09 Husa</last_name>
      <phone>4711</phone>
      <phone_ext>09</phone_ext>
      <email>raija.husa@hus.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Heikki Joensuu</investigator_full_name>
    <investigator_title>Professor, Research Director</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>docetaxel</keyword>
  <keyword>pertuzumab</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>HER2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

